Sanofi enters agreement with Janssen to develop E. coli vaccine candidate
03 Oct 2023
VaccineLicense out/in
Preview
Source: PMLiVE
Sanofi has reached an agreement to develop and commercialise an experimental vaccine candidate for extraintestinal pathogenic E. coli developed by Janssen Pharmaceuticals.
Under the terms of the deal, Sanofi will pay the Johnson & Johnson unit $175m upfront, followed by development and commercial milestones. Both parties will co-fund current and future research and development costs.
Extraintestinal pathogenic E. coli is a common gram-negative bacterial pathogen in humans and a leading cause of sepsis, particularly in older adults.
Sepsis, sometimes referred to as septicaemia or blood poisoning, is a life-threatening bloodstream infection accompanied by severe illness and widespread organ damage, resulting from the immune system’s overreaction to an infection.
Antimicrobial resistant (AMR) E. coli strains are also an ongoing healthcare concern, with extraintestinal pathogenic E. coli a major driver behind the global AMR crisis, which has been declared by the World Health Organization as one of the top ten threats to global public health.
Associated with the deaths of 4.95 million people in 2019, AMR occurs when bacteria, viruses, fungi and parasites change and adapt to antibiotics over time. As a result, infections become harder to treat and the risk of disease spread, severe illness and death increases.
The ongoing late-stage E.mbrace trial, which Janssen started in 2021, is evaluating the efficacy of the 9-valent extraintestinal pathogenic E. coli vaccine (ExPEC9V) compared to placebo in the prevention of invasive E. coli disease caused by ExPEC9V O-serotypes.
He continued: “This agreement with Janssen aims to positively impact public health by reducing hospitalisation costs and the burden on health systems associated with ExPEC and help older adults around the world to live longer, healthier lives.”
The deal comes less than a month after Sanofi partnered with Ad Scientiam to launch an international, multicentre, longitudinal study evaluating the ability of medical software MSCopilot to assess disability progression in patients with multiple sclerosis (MS).
Sanofi also expanded its collaboration agreement with Scribe Therapeutics in July to advance in vivo genetic medicines for sickle cell and other genomic diseases, with the deal potentially worth over $1.2bn.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.